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Spain; #Institutu Onkologikoa, San Sebastián, Spain; **Servicio de Oncologı́a Radioterápica, Centro
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Volume 110  Number 3  2021 Localized prostate cancer: 10-year follow-up 719Methods and Materials: This was a prospective observational study of a cohort of men who received a diagnosis of clinically
localized prostate cancer (clinical stage T1 or T2, low and intermediate risk group) and were treated with radical prostatec-
tomy (n Z 139), brachytherapy (n Z 317), or external radiation therapy (n Z 194). Treatment decisions were jointly made
by patients and physicians. Patient-reported outcome (PRO) evaluation included the Expanded Prostate Cancer Index Com-
posite and Short Form-36, administered centrally by telephone interviews before and annually after treatment. The Expanded
Prostate Cancer Index Composite covers urinary, bowel, sexual, and hormonal domains. To assess PRO changes over time,
while accounting for correlation among repeated measures, generalized estimating equation models adjusted by propensity
scores were constructed.
Results: The PRO completion rate at 10 years was 85.8%. Generalized estimating equation models showed that the pattern of
radical prostatectomy side effects, with substantial urinary incontinence and sexual dysfunction, remained until 10 years after
treatment (standard deviation [SD], e1.1 and e1.3, respectively). Brachytherapy produced late deterioration in urinary conti-
nence (SD, e0.4) and sexual function (SD, e0.9) that appeared midterm, but the differences from radical prostatectomy re-
mained statistically significant at 10 years (P < .001 after adjusting by propensity score). External radiation therapy showed
similar results to brachytherapy, but with bowel bother (SD, e0.3).
Conclusions: Although late deterioration in radiation therapy groups attenuated differences from radical prostatectomy, rele-
vant PRO differences still remained after 10 years. Our findings support that brachytherapy is the treatment option that causes
the least impact on PROs; it is therefore an alternative to be considered when making evidence-based decisions on localized
prostate cancer treatment.  2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Prostate cancer is the most frequently diagnosed cancer
among men in the United States and Europe.1 Currently,
most patients with prostate cancer are diagnosed in local-
ized stages2 and will probably be long-term survivors.3
Randomized controlled trials of curative intention
treatments for localized prostate cancer are mainly
restricted to the Prostate Testing for Cancer and Treatment
(ProtecT) trial.4,5 This study showed similar very high rates
of survival at 10 years of follow-up4 for radical prostatec-
tomy, external radiation therapy, and active monitoring;
however, treatments differed in side-effect patterns as
measured by patient-reported outcomes (PROs).5 These
results have been confirmed by an analysis of the trial re-
sults according to the treatment received and including
patients who refused the randomization.6 Long-term PRO
follow-ups have been also reported by the Cancer of the
Prostate Strategic Urologic Research Endeavor (CaP-
SURE)7 trial and Prostate Cancer Outcomes Study,8 but
CaPSURE is the only study to evaluate brachytherapy.
A systematic review of PROs in clinically localized
prostate cancer treatments9 identified 6 studies evaluating
brachytherapy with follow-ups of 5 to 6 years, and their
combined results indicated a reduced adverse effect profile.
In contrast, 5 and 10 years after treatment, patients under-
going brachytherapy in the CaPSURE study7 presented a
similar risk of sexual deterioration compared with those
who received radical prostatectomy, a lower risk of urinary
function worsening, and a higher risk of bowel dysfunction.
Since that review and up to the present, no other study on
brachytherapy has shown relevant evidence on this treat-
ment. Three articles have published data at 12 to 14,10 8,11
and 8 to 912 years of follow-up, but they presented relevantlimitations: a small sample size (4210 or 612 patients in the
brachytherapy group at the last follow-up), a very low
response rate (13%),11 or only covering bowel impact.12
Therefore, evidence on brachytherapy remains scarce and
controversial in the long term.
The aim of this study was to assess the long-term impact
of the side effects of radical prostatectomy, brachytherapy,
and external radiation therapy on patients with localized
prostate cancer 10 years after treatment, using propensity
score analyses.
Methods and Materials
This was a prospective observational study (ClinicalTrials.
gov Identifier: NCT01492751) of a cohort of men who
received a diagnosis of clinically localized prostate cancer
and were treated with radical prostatectomy (n Z 193),
brachytherapy (n Z 317), or external radiation therapy (n
Z 194). Study details have been described elsewhere.13-15
Briefly, eligible patients were those with clinical stage T1
or T2, low and intermediate D’Amico risk group disease,16
treated at one of the participating centers, and without
previous prostate transurethral resection. Decisions
regarding treatment were made jointly by patients and
physicians. The study was approved by the ethics review
boards of the participating hospitals, and written informed
consent was obtained from patients per the 2000 revision of
the Helsinki Declaration.
The Expanded Prostate Cancer Index Composite
(EPIC)17,18 and Short Form-36 (SF-36)19,20 were adminis-
tered centrally by telephone interviews before treatment
and during follow-up at 1, 3, 6, and 12 months after
treatment during the first year and annually thereafter. EPIC
covers urinary, bowel, sexual, and hormonal domains, with
Garin et al. International Journal of Radiation Oncology  Biology  Physics72050 items and scores ranging from 0 to 100.17 The SF-36
(version 2) generates physical and mental component
summaries, scored as recommended by developers and
standardized to have a mean of 50 and standard deviation
(SD) of 10 in the general US population.19 Higher scores
indicate better results in both instruments. In addition to the
EPIC scores, we selected the key EPIC items already
identified in the ProtecT study5 to aid in the interpretation
of clinical relevance. Responses to these key items were all
dichotomized to show the percentage of men reporting
problems, except for the erection firmness item (percentage
of men reporting sexual potency).
The sample size was calculated to detect between-group
differences of 5 points on the urinary irritativeeobstructive
score of the EPIC questionnaire.13
Statistical analysis
Summary statistics and 95% confidence intervals (CIs) are
reported by treatment group. To account for treatment se-
lection bias, previously estimated propensity scores,15
which had already been demonstrated to balance the dis-
tribution of possible confounders among treatment groups,
were incorporated into multivariate analyses.
To assess PRO changes over time, while accounting for
correlation among repeated measures, separate generalized
estimating equation (GEE) models were constructed for
each EPIC score or key item (included as dependent vari-
ables). Time was included in the model as a categorical
variable, and interactions between treatment and time were
considered to test differences on trends among the treat-
ment groups. The GEE models were constructed with the
use of SAS/STAT software, version 9.4.
Results
At baseline, the treatment groups presented statistically
significant differences in age (means from 64.2 years in
radical prostatectomy to 70.1 years in external radiation
therapy; P < .001), prostate-specific antigen level (means
from 7.0 ng/mL in brachytherapy to 8.1 ng/mL in external
radiation therapy; P < .001), and Gleason score (means
from 5.5 in brachytherapy to 6.3 in radical prostatectomy;
P < .001). After propensity score adjustment,15 the differ-
ences in baseline clinical characteristics among treatment
groups disappeared.
The flow chart in Figure E1 shows that at 10 years after
treatment, 149 of 704 participants had died, 74 missed the
interview, 5 were lost to follow-up, and 476 completed the
PRO questionnaires. The completion rate at 10 years was
85.8% (median, 10.24 years; interquartile range, 10.28-10.14).
Figure 1 shows the annual results of the EPIC urinary
domain with unadjusted means or percentages with their
95% CI and P-values adjusted by propensity scores. Uri-
nary incontinence (Fig. 1A) presented statistically signifi-
cant timeetrend differences among the treatment groups,with patients who underwent radical prostatectomy pre-
senting the greatest deterioration. The use of absorbent pads
(Fig. 1B) was null before treatment and increased 10 years
after to 34.3% in the prostatectomy group, 6.9% in the
brachytherapy group, and 7.8% in the external radiation
therapy group. Although the urinary irritativeeobstructive
score was quite stable during follow-up (Fig. 1C), the
radiation therapy groups presented statistically lower
(worse) means than radical prostatectomy. Figure 1D shows
the rate of men reporting pain or burning with urination,
which was quite low during the whole follow-up (<7% for
all groups).
All scores and selected key items from the EPIC sexual
domain showed statistically significant different results
over 10 years of follow-up across the treatment groups
(Fig. 2). The sexual function score decreased (deteriorated)
with radical prostatectomy and external radiation therapy,
but patients treated with brachytherapy showed stability
during the first 5 years after treatment and deterioration
thereafter (Fig. 2A). Before surgery, 58.1% of men reported
erections firm enough for intercourse, but this rate fell to
9.4% after 1 year (Fig. 2B). In the brachytherapy group,
this rate remained stable at around 40% from before
treatment to the fifth year and declined thereafter.
Figure 3 shows that only the key item about loose stools
(Fig. 3B) and the bowel summary score (Fig. 3G) presented
statistically significant differences among treatments over
time (P Z .027 and PZ .032), both indicating worse results
in the external radiation therapy group. Calculating the
P-value of trend differences for fecal incontinence (Fig. 3C)
and bloody stools (Fig. 3D) was not possible, because in
some evaluations no men reported these problems.
Figure 4 shows the changes at 10 years obtained by GEE
models constructed to assess treatment impact on PROs
after adjusting by propensity scores. The GEE models with
all the coefficients and P-values are available in the Table
E1. Units of change on the left of the figure are EPIC
scores and those on the right SDs (change: moderate Z 0.5
SD and large Z 1 SD, indicated by gray lines).21 On
average, 10 years after radical prostatectomy, patients
scored 29.9 points less than before treatment (Fig. 4A).
This change of 30 points is greater than 1 SD (large dete-
rioration). Patients treated with brachytherapy fared þ17.4
points (95% CI, 11.0-23.9) better (positive sign) than those
who underwent radical prostatectomy (reference group)
and, similarly, those who underwent external radiation
therapy. Urinary continence deterioration in the brachy-
therapy and external radiation therapy groups has an near
0.5 SD (moderate deterioration).
Figure 4B shows that both radiation therapy groups
presented worse results than radical prostatectomy on the
urinary irritativeeobstructive score (e3.9 points for
brachytherapy; e5.5 points for external radiation therapy).
Figure 4C shows substantial worsening of the EPIC sexual
function score at 10 years in the 3 treatment groups, but
patients treated with brachytherapy fared þ10.8 points
(95% CI, 4.8-16.8) better than those in the radical
A EPIC Urinary Incontinence Score C EPIC Urinary Irritative/Obstructive Score
B EPIC Item: ≥ 1 pad per Day D EPIC Item: pain or burning on urination
E EPIC Urinary Summary Score 
——■—— Radical Prostatectomy
— ▲ — Brachytherapy



























































































































Fig. 1. Ten years of annual results in the urinary domain. Effects of treatments on the urinary domain measured with the
Expanded Prostate Cancer Index Composite (EPIC) instrument. EPIC urinary scores comprise several urinary items and are
formed by linear transformation of raw scores, ranging from 0 to 100 (from worse to better). (A) EPIC score for urinary
incontinence. (B) Results for one of the items included in that score: Percentage of men who used 1 absorbent pads per day
for urinary incontinence. (C) EPIC urinary irritative-obstructive score. (D) Percentages for men who reported moderate-to-
severe pain or burning on urination. (E) EPIC urinary summary score. P-values show the strength of evidence for a difference
in mean response over 10 years of follow-up across the 3 groups, adjusted by propensity score. I bars represent unadjusted
95% confidence intervals.
Volume 110  Number 3  2021 Localized prostate cancer: 10-year follow-up 721prostatectomy group. Finally, worsening was not observed
in the bowel function domain (Fig. 4E), and the small
worsening presented in bowel bother (<0.5 SD) did not
statistically differ among treatments (Fig. 4F).Discussion
Our findings show that the main traits of radical-
prostatectomy side-effect patterns, with large urinary incon-
tinence and sexual dysfunction, remain until 10 years after
treatment. Brachytherapy produced substantial deteriorationin sexual function and moderate urinary incontinence that
appears at midterm (5 and 7 years after treatment). External
radiation therapy showed results similar to brachytherapy,
but with bowel bother. Although late deterioration in the
radiation therapy groups attenuated their differences from
radical prostatectomy, they remained relevant at 10 years.
The main limitation of this study is its observational
design. The main concern regarding this design is treatment
selection bias where, for example, brachytherapy is pref-
erentially prescribed to patients with lower tumor risk and
surgery to younger patients.13-15 In our cohort, the pro-
pensity scores balanced treatment selection bias.15 Results
A EPIC Sexual Function Score C EPIC Sexual Bother Score
B EPIC Item: Erection Firmness D EPIC Item: Problem with Erectile Dysfunction


































































































































Fig. 2. Ten years of annual results in the sexual domain. Effects of treatments on the sexual domain measured with the
Expanded Prostate Cancer Index Composite (EPIC) instrument. EPIC sexual scores comprise several sexual items and are
formed by linear transformation of raw scores, ranging from 0 to 100 (from worse to better). (A) EPIC sexual function score.
(B) Results for one of the items included in this score: Percentage of men reporting erections firm enough for intercourse. (C)
EPIC sexual bother score. (D) Percentages for men who reported a moderate-to-severe problem with erectile dysfunction. (E)
EPIC sexual summary score. P-values show the strength of evidence for a difference in mean response over 10 years of
follow-up across the 3 groups, adjusted by propensity score. I bars represent unadjusted 95% confidence intervals.
Garin et al. International Journal of Radiation Oncology  Biology  Physics722adjusted by propensity scores were consistent with those
from traditional models adjusted by baseline clinical vari-
ables (Table E2), likely allowing an estimation of the true
treatment effects.22 Second, the treatments were applied >1
decade ago; since then, diagnostic techniques and treat-
ments for prostate cancer have evolved.
The strengths of the study include the collection of data
per the present recommendations of the International
Consortium for Health Outcomes Measurement for local-
ized prostate cancer, which were developed in 2015,23 the
use of a propensity score adjustment for comparative
effectiveness research,22 regular follow-up with high rates
of response (median, 83.3%; interquartile range, 85.7-74.0),and the consistency of interpretation based on the magni-
tude of change with previously established minimally
important differences for EPIC scores.24 This is the first
study to provide robust evidence on the long-term outcomes
of brachytherapy because only 85 of 684 patients treated
with this therapy in the CaPSURE registry were evaluated
10 years after treatment.7 Of the 317 patients treated with
brachytherapy in our cohort, 69 died and 217 completed the
10-year evaluation.
CaPSURE applied the University of California, Los
Angeles, Prostate Cancer Index to measure clinically
meaningful declines in PROs (defined as 0.5 SD) after
treatment.7 To facilitate the comparison with CaPSURE, we
A EPIC Bowel Function Score E EPIC Bowel Bother Score 
B EPIC Item: Loose Stools F  EPIC Item: Bowel Habits
EPIC Item: Fecal Incontinence G EPIC Bowel Summary Score 




































































































































































































Fig. 3. Ten years of annual results in the bowel domain. Effects of the treatments on the bowel domain measured with the
Expanded Prostate Cancer Index Composite (EPIC) instrument. EPIC bowel scores comprise several bowel items and are
formed by linear transformation of raw scores, ranging from 0 to 100 (from worse to better). (A) EPIC score for bowel
function. (B-D) Results for items included in that score as percentages of men who reported having (B) loose stools half the
time or more, (C) fecal incontinence at least once per week, and (D) bloody stools half the time or more. (E) EPIC bowel
bother score. (F) Percentages for men who reported a moderate-to-severe negative effect on bowel habits. (G) EPIC bowel
summary score. P-values show the strength of evidence for a difference in mean response over 10 years of follow-up across
the 3 groups, adjusted by propensity score. I bars represent unadjusted 95% confidence intervals.
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A EPIC Urinary Incontinence Score B EPIC Urinary Irritative/Obstructive Score 
C EPIC Sexual Function Score D EPIC Sexual Bother Score 
E EPIC Bowel Function Score F EPIC Bowel Bother Score 




















































































Fig. 4. Impact on patient-reported outcomes 10 years after treatment. On the left side of the figures, the units of change are
EPIC scores and on the right side, they are standard deviations (moderate Z 0.5 SD; large Z 1 SD, indicated by gray lines).
Mean changes in Expanded Prostate Cancer Index Composite instrument scores from pretreatment to 10 years of follow-up,
obtained by generalized estimating equation models, are adjusted by propensity scores. Each bar is complemented with the
difference compared with radical prostatectomy (mean and 95% confidence interval).
Garin et al. International Journal of Radiation Oncology  Biology  Physics724similarly calculated odds ratios adjusted by propensity scores
(Table E3) with radical prostatectomy as the reference group.
Because EPICwas derived from the University of California,
Los Angeles, Prostate Cancer Index, mainly by transforming
the urinary domain, only the sexual and bowel domains are
comparable. The results for sexual function were similar for
the radiation therapy groups, and differences were not sta-
tistically significant at 10 years in our cohort, nor in the
CaPSURE study, with an odds ratio of 0.8 (95% CI, 0.3-1.7)
and 0.9 (95%CI, 0.3-2.6)7 in brachytherapy and 1.3 (95%CI,
0.5-3.2) and 0.7 (95% CI, 0.2-3.4)7 in external radiation
therapy. Our bowel results in the external radiation therapygroup were also similar to those reported by CaPSURE, but
not in the brachytherapy group.
The probability of experiencing a meaningful decline
after brachytherapy compared with radical prostatectomy at
10 years after treatment was higher among the CaPSURE
patients than in our cohort, with odds ratios of 3.3 (95% CI,
1.4-7.4)7 versus 2.3 (95% CI, 0.8-6.7) in bowel function and
2.3 (95% CI, 1.0-5.2)7 versus 1.5 (95% CI, 0.5-4.0) in bowel
bother. Therefore, discrepancies compared with CaPSURE
were mainly restricted to the better results obtained in our
study for brachytherapy in the bowel domain. Although
CaPSURE is a nationwide prostate cancer registry, it is
Volume 110  Number 3  2021 Localized prostate cancer: 10-year follow-up 725important to highlight the low number of patients in the
brachytherapy group with results at 10 years7 ranged from 76
to 85 according to the domain evaluated. Follow-up losses
could have produced some bias in CaPSURE, which may
explain the differences when compared with our study. For
example, completion rate could be higher among patients
with worse PRO results, because patients without problems
may tend to disregard clinical encounters.
In addition, patients who underwent brachytherapy in
our cohort presented a similar sexual pattern to results re-
ported by Keyes et al25 in a large cohort of almost 3000
patients followed for a median of 3.5 years and a maximum
of 14 years, when focusing on patients with full potency
before treatment and without neoadjuvant androgen depri-
vation therapy: a gradual and continuous erectile function
decline. In our study, the percentage of men reporting
sexual potency in this selected subsample went from 64% at
1 year after treatment to 53% after 4 years and 34% after 7
years. In the study by Keyes et al, the most significant drop
in erectile function among patients with full potency before
treatment was also during the first months: approximately
65% reported full potency 1 year after treatment, approxi-
mately 55% at 4 years, and 40% at 7 years after treat-
ment.25 This similarity is especially noteworthy because the
erectile function measurement in both studies has a
different nature. Ours is an item response in a PRO (EPIC),
and Keyes et al assessed erectile function through a
physician-reported 3-point scale.25
Our long-term findings in PROs confirm those reported
by the ProtecT trial at 6 years5,6 regarding the distinct
impact of localized prostate-cancer treatment side effects,
but similar general health. Figure E2 and Table E1 show the
stability of the SF-36 summaries until the sixth year of
follow-up. Both studies show a very similar negative effect
of prostatectomy on sexual domain (ie, only 14.7% of men
reported sexual potency at year 6 in our study and 15% in
the ProtecT trial).6 Regarding radical prostatectomy’s
impact on urinary continence, the percentage of patients
who required the use of pads was lower in the ProtecT trial
than in our cohort (21%6 vs 32% by year 6). In both studies,
external radiation therapy is related to bowel bother and
function deterioration at 6 years after treatment (ie, 5.9% of
men reporting bloody stools more than half the time in the
ProtecT trial6 and 3.8% in our study).
Of note, the ProtecT trial’s inclusion criteria were
limited to patients diagnosed by screening. As a conse-
quence, the baseline tumor characteristics of patients in the
ProtecT trial and our cohort are very different, including
median prostate-specific antigen levels of 4.8 versus 8.1
ng/mL, 78% versus 43.3% of patients with Gleason score
6, and 79% versus 58.2% with clinical T1 stage.4Conclusions
Novel long-term results are provided on the impact of
brachytherapy adverse effects in patients with localizedprostate cancer 10 years after treatment compared with
radical prostatectomy and external radiation therapy. Our
findings support that, despite some late deterioration in
urinary continence and sexual function around 5 years after
treatment, brachytherapy is the treatment option causing
the least impact on PROs. These results provide patients,
clinicians, and health care planners with clear information
to make evidence-based decisions and facilitate shared
clinical decision-making, taking into account patients’
perspective. Although no single treatment can be consid-
ered the preferred strategy for managing all patients, our
study supports brachytherapy as a possible alternative for
patients with localized prostate cancer seeking attempted
curative treatment while avoiding bowel effects and post-
poning the risk for urinary incontinence and sexual
dysfunction.References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A.
Global cancer statistics 2018: GLOBOCAN estimates of incidence
and mortality worldwide for 36 cancers in 185 countries. CA Cancer J
Clin 2018;68:394-424.
2. Shao YH, Demissie K, Shih W, et al. Contemporary risk profile of
prostate cancer in the United States. J Natl Cancer Inst 2009;101:
1280-1283.
3. Chou R, Croswell JM, Dana T, et al. Screening for prostate cancer: A
review of the evidence for the U.S. Preventive Services Task Force.
Ann Intern Med 2011;155:762-771.
4. Hamdy FC, Donovan JL, Lane JA, et al. 10-year outcomes after
monitoring, surgery, or radiotherapy for localized prostate cancer. N
Engl J Med 2016;375:1415-1424.
5. Donovan JL, Hamdy FC, Lane JA, et al. Patient-reported outcomes
after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J
Med 2016;375:1425-1437.
6. Neal DE, Metcalfe C, Donovan JL, et al. Ten-year mortality, disease
progression, and treatment-related side effects in men with localised
prostate cancer from the ProtecT randomised controlled trial according
to treatment received. Eur Urol 2020;77:320-330.
7. Punnen S, Cowan JE, Chan JM, Carroll PR, Cooperberg MR. Long-
term health-related quality of life after primary treatment for localized
prostate cancer: Results from the CaPSURE registry. Eur Urol 2015;
68:600-608.
8. Resnick MJ, Koyama T, Fan KH, et al. Long-term functional out-
comes after treatment for localized prostate cancer. N Engl J Med
2013;368:436-445.
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